Britzen-Laurent N, Herrmann C, Naschberger E, Croner RS, Stürzl M (2016)
Publication Type: Journal article
Publication year: 2016
Book Volume: 22
Pages Range: 6434-43
Journal Issue: 28
Guanylate-binding proteins (GBPs) are interferon-stimulated factors involved in the defense against cellular pathogens and inflammation. These proteins, particularly GBP-1, the most prominent member of the family, have been established as reliable markers of interferon-?-activated cells in various diseases, including colorectal carcinoma (CRC) and inflammatory bowel diseases (IBDs). In CRC, GBP-1 expression is associated with a Th1-dominated angiostatic micromilieu and is correlated with a better outcome. Inhibition of tumor growth by GBP-1 is the result of its strong anti-angiogenic activity as well as its direct anti-tumorigenic effect on tumor cells. In IBD, GBP-1 mediates the anti-proliferative effects of interferon-? on intestinal epithelial cells. In addition, it plays a protective role on the mucosa by preventing cell apoptosis, by inhibiting angiogenesis and by regulating the T-cell receptor signaling. These functions rely to a large extent on the ability of GBP-1 to interact with and remodel the actin cytoskeleton.
APA:
Britzen-Laurent, N., Herrmann, C., Naschberger, E., Croner, R.S., & Stürzl, M. (2016). Pathophysiological role of guanylate-binding proteins in gastrointestinal diseases. World Journal of Gastroenterology, 22(28), 6434-43. https://doi.org/10.3748/wjg.v22.i28.6434
MLA:
Britzen-Laurent, Nathalie, et al. "Pathophysiological role of guanylate-binding proteins in gastrointestinal diseases." World Journal of Gastroenterology 22.28 (2016): 6434-43.
BibTeX: Download